How has the ADVISE trial changed your approach to steroid sparing agents for non-infectious uveitis?

The ADVISE trial was a well-designed, multinational trial that compared adalimumab therapy for non-infectious intermediate, posterior, or panuveitis versus conventional immunosuppressive therapy or CID. Two hundred twenty-seven subjects were enrolled over four years, and a fifth year was required to...

So I used to work in a uveitis clinic one day per week, and that was an amazing experience. I really do like the idea of doing adalimumab or biologics first line, but the main barrier is insurance coverage. That being said, we still do the dual therapy with DMARD (mtx or mmf) plus TNFi as if the pat...